Sophia Genetics Q2 2024 GAAP EPS $(0.23) Beats $(0.28) Estimate, Sales $15.808M Miss $17.400M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sophia Genetics (NASDAQ:SOPH) reported Q2 2024 GAAP EPS of $(0.23), beating the estimate of $(0.28). However, sales of $15.808M missed the $17.400M estimate, though they increased by 5.01% year-over-year.
August 06, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Sophia Genetics reported a better-than-expected EPS of $(0.23) against the $(0.28) estimate, but missed sales expectations with $15.808M versus $17.400M. Sales increased by 5.01% year-over-year.
The better-than-expected EPS is a positive sign, but the miss on sales could weigh on investor sentiment. The year-over-year sales increase is a positive factor, but the overall impact is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100